A Systematic Review of Thulium Fiber Laser: Applications and Advantages of Laser Technology in the Field of Urology

Abstract

Laser technology is widely used in urological surgery, from lithotripsy, prostate surgery to en-bloc resection of tumours. While Holmium:YAG has been widely employed over the last two decades, in recent years, there has been a surge of interest in Thulium Fiber Laser (TFL), which offers theoretical advantages of better water absorption and lower stone ablation thresholds. A systematic review was conducted to assess the evidence from clinical research on TFL’s application for lithotripsy and prostate surgery. It identified 357 articles and 8 (1506 patients) were selected, of which 4 clinical studies each investigated TFL enucleation of prostate (ThuFLEP) and TFL lithotripsy. For flexible ureteroscopic lithotripsy (FURSL), stone ablation settings ranged from 0.1–4 J, and 7–300 Hz, mean operative time ranged from 23.4–39.8 minutes and lasing time ranged from 1.2–10 minutes. For stone dusting in percutaneous nephrolithotomy (PCNL), settings of 0.2 J and 125–200 Hz were found to be optimal. For ThuFLEP, all studies showed a significant improvement in IPSS (International Prostate Symptom Score), urinary flow rate (Q_max), quality of life measures, and post-void residual volume, with mean operative time ranging from 67–104.5 minutes. Our review shows that there is limited evidence on the use and clinical outcomes of TFL. ThuFLEP might suggest equivalence to the widely used HoLEP in the available evidence so far. TFL lithotripsy shows promising results but further prospective, randomized trials are required to properly assess its usability, clinical effectiveness and standardisation of the settings for successful adoption of the technology.

Keywords:

• ureteroscopy
• percutaneous nephrolithotomy
• kidney calculi
• BPH
• TFL
• thulium fiber laser

Introduction

Minimally invasive surgery (MIS) has seen large uptake in recent decades, with increasing numbers of such procedures being performed.¹ Laser technology is widely used in the management of urological diseases, including urolithiasis, benign prostatic enlargement (BPE), and urinary tract malignancies.² Laser lithotripsy was first adopted by urologists in the 1980s,^3,4 with Holmium:Yttrium-Aluminium-Garnet (Ho:YAG) becoming the laser of choice in the mid 1990s.^5,6 In recent years, there has been a surge of interest in Thulium Fiber Laser (TFL) which has a 4x higher absorption coefficient in water-containing tissue, smaller operating fibers (50–150 μm core diameter), lower energy pulses (0.025 J), and higher pulse rate capability (up to 2 KHz). The theoretical benefits of TFL have seen its application outside of stone surgery, in soft tissue surgery such as BPE and bladder tumour en-bloc resection.^7,8 TFL has demonstrated efficacy and safety in ex vivo research and is now being deployed in clinical research.^9,10

One advantage of TFL is its higher water-absorption coefficient compared with Ho:YAG, which means that water absorbs TFL energy around four times higher than it does with Ho:YAG laser energy. Using water absorption as a model for cell absorption, the implication of this is that more energy from TFL is absorbed by cells and therefore they are better ablated. A further implication is that this leads to lower vapor-channel-initiation thresholds,^11,12 leading to the “Moses” effect detailed below. A further advantage is the lower ablation thresholds for many different urinary stone compositions compared with Ho:YAG. For example, hard stone compositions such as calcium oxalate monohydrate and soft stone compositions such as uric acid have much lower stone ablation thresholds, and are therefore easier to ablate than with Ho:YAG.^11,13–15 This allows either lower settings with equal stone ablation results to Ho:YAG, or higher stone ablation volume at the same settings.

The ability to produce equal stone ablation at lower energy settings leads to two pragmatic benefits of TFL. Firstly, the lower energy settings lead TFL to being less prone to stone retropulsion. Stone retropulsion describes the effect where calculi are being pushed away, in addition to being ablated, by high-energy laser bursts. As described in an in vitro study with the conventional Ho:YAG laser, retropulsion increases linearly with pulse energy.¹⁴ This is a troublesome effect for the endoscopist, leading the need to “chase” stones or for the stones to go proximally in the kidney. In addition to this, fewer small fragments are propelled into view of the endoscope, reducing the storm of fragments often seen through the endoscope, improving the endoscopic view during lithotripsy.¹⁶

The “Moses effect” was first described in 1986 and describes delivering short, low energy pulses to create a bubble through which to deliver the ablative burst.¹⁷ While travelling through the parted water, the laser is not absorbed, therefore increasing the intensity of energy delivered to a calculus. This “Moses” effect is also reported by the uniform pulse energies of TFL, and due to the lower power, uniformity, and lack of a peak, there is local pressure an order of magnitude lower than Ho:YAG.^16–21

Materials and Methods

Evidence Acquisition

Inclusion Criteria

1. Study the use of Thulium Fiber Laser.

2. Clinical research.

3. English language articles.

Exclusion Criteria

1. Animal or laboratory studies or non-clinical research.

2. Case reports, review articles, conference abstracts.

3. Investigated non-urinary tract applications.

Search Strategy and Study Selection

The systematic review was performed in accordance with the Cochrane Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).^19,20 Figure 1 details the search strategy and the PRISMA flowchart. Searches were performed for results between the inception of the databases and January 2021. “MeSH” or database-equivalent terms included “Prostatic hyperplasia”, “Lithotripsy”, “stone” and “Urolithiasis”. Specific search terms included “thulium”, “fiber”, “laser”, “BPH”, and “TFL”. These databases included: MEDLINE, EMBASE, Scopus, CINAHL and Cochrane Library. A manual search of “grey literature” was also performed.

Figure 1 PRISMA flowchart of the included studies.

Note: Adapted from Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. Creative Commons licence and disclaimer available from: http://creativecommons.org/licenses/by/4.0/legalcode.²⁰

Results

The initial set of 357 articles were identified through searches of various databases. After removal of duplicates, 294 articles were screened of which 246 abstracts were further evaluated. Sixty full text articles were obtained and finally eight studies (1506 patients) were selected for our review. These studies were published between 2018–2021. The PRISMA diagram is displayed in Figure 1.

There were four studies published on lithotripsy (two on Percutaneous Nephrolithotomy [PCNL] and two on Flexible Ureteroscopy with Lithotripsy [FURSL]) and four studied the use of Thulium Laser Enucleation of Prostate (ThuFLEP).

Stone Surgery

Results of stone surgery studies are presented in Table 1. Laser settings ranged from 0.1–4 J, and 7–300 Hz. One study that specifically investigated optimal settings for stone dusting in PCNL found 0.2 J and 125–200 Hz to be optimal.²¹ Stone volume ranged from 179–2338 mm³, stone density ranged from 880–1301 Hounsfield Units (HU), mean operative time (MOT) ranged from 23.4–39.8 minutes. Laser on time (LOT) ranged from 1.2 to 10 minutes. Other outcomes and complications are reported in Table 1.

Table 1 Summary of clinical research of TFL for Urolithiasis.

Author	Year	Area	Design	N	Settings	Stone Characteristics		Outcomes			Complications (C-D)
						Volume (mm^3)	Density (HU)	MOT (min)	LOT (min)	Other
Shah^Citation21	2020	PCNL	Prospective	54	0.1 to 1 J; 100 to 300 Hz.	2338 ± 1997	1301 ± 435	39.85 ± 20.52	10.08 ± 7.41	Stone fragmentation rate was 5.02 ± 3.93 mm^3/s. Optimal initial laser setting: 0.2 J and 125–200 Hz	Grade II: 3
Enikeev^Citation24	2020	PCNL	Prospective	120	6–40 W; 7–300 Hz; 0.1–4.0 J	NR	1019 ± 375	23.4 ± 17.9	5.0 ± 5.7	Mean total energy for stone ablation 3.6 ± 4.3 kJ	Grade I: 14 Grade II: 5 Grade IIIa: 6
Enikeev^Citation25	2020	FURSL	Prospective	40	Peak/average power of 500/50 W. Two dusting regimens: 0.5 J x 30 Hz = 15 W and 0.15 J x 200 Hz = 30 W	883 (IQR: 606–1664)	880 ± 381	24.1 ± 10.9	4 (1.6–6.4)*	Median total energy for stone ablation: 5.6 (IQR 2.3–10.0) kJ	Grade I: 3 Grade II: 1
Enikeev^Citation26	2020	FURSL	Prospective	149	NR	179 (94–357)*	985 ± 360	<60	1.2 (0.5–2.7)*	Median (IQR) total energy for lithotripsy 1.0 (0.4–2) kJ; median stone ablation speed 140 (80–279) mm^3/min, median ablation efficacy 5.6 (3–9.9) J/mm^3; median energy consumption 0.9 (0.6–1) J/min.	Grade I–II: 6

Note: *median (IQR).

Abbreviations: TFL, Thulium Fiber Laser; PCNL, percutaneous nephrolithotomy; FURSL, Flexible Ureteroscopy with Lithotripsy; C-D, Clavien-Dindo; LUTS; NR, not reported; MOT, mean operative time; LOT, Laser on time; HU, Hounsfield Units.

Prostate Laser Enucleation

Results of prostate laser enucleation studies are presented in Table 2. One study used the FiberLase U1, and three studies used the Urolase TFL. Mean Prostate Specific Antigen (PSA) ranged from 4.5–5.2. Mean prostatic volume ranged from 59.5–127.8 cm³. Mean operative time ranged from 67–104.5 minutes. All studies showed a significant improvement in IPSS (International Prostate Symptom Score), urinary flow rate (Q_max), quality of life measures, and post-void residual volume. In a randomized study, Enikeev et al. found ThuFLEP to have a significantly easier learning curve than HoLEP and monopolar enucleation of prostate (MEP).²² In a retrospective study, Enikeev et al. found ThuFLEP to significantly improve erectile function.²³

Table 2 Summary of clinical research of TFL for Prostate surgery

Author	Year	Application	Design	N	Baseline		Outcomes					Complications (C-D)
					PSA	Prostate Volume (cm^3)	MOT (min)	IPSS	QoL	Qmax (mL/s)	PVR (mL)
Morozov^Citation8	2020	ThuFLEP	ThuFLEP vs HoLEP vs MEP	812	5.2 ± 5	86 ± 40	67 ± 29	Pre: 23.1 ± 1.8 Post: 5 ± 2	Pre: 4.03 ± 0.8 Post: 1.6 ± 0.6	Pre: 10 ± 2.7 Post: 22.2 ± 3.2	Pre: 74 ± 20.7 Post: 11.9 ± 9.3	Grade 1: 1.85% Grade II: 3.66% Grade IIIa: 2%*
Enikeev^Citation29	2019	ThuFLEP	ThuFLEP vs OP	90	NR	127.8 ± 40.2	103.2 ± 36.6	Pre: 21.8 ± 1.1 Post: 10.7 ± 2.6 p <0.001	Pre: 3.9 ± 0.8 Post: 1.6 ± 0.7 p = 0.032	Pre: 7.5 ± 1.9 Post: 17.7 ± 2.3 p < 0.001	Pre: 73.4 ± 29.4 Post: 16.8 ±10.9 p <0.001	Grade I: 18 Grade II: 2 Grade III: 3
Enikeev^Citation23	2018	ThuFLEP	ThuFLEP vs TURP	211	4.7 ± 2.7	90 ± 42.9	72	Pre: 21.8 ± 1.6 Post: 10.9 ± 3.0 p <0.001	Pre: 3.9 ± 0.8 Post: 1.7 ±0.6 p<0.001	Pre: 7.8 ± 1.9 Post: 16.6 ± 1.5 p < 0.001	Pre: 68.7 ± 21.5 Post: 15.3 ± 13.6 p<0.001.	NR**
Enikeev^Citation22	2018	ThuFLEP	ThuFLEP vs HoLEP vs MEP	30	4.5 ± 2.8	59.5 ± 11.7	104.5 ± 33.6	Pre: 22.8 ± 1.8 Post: 11.9 ± 4.6 p < 0.01	Pre: 3.2 ± 0.8 Post: 1.5 ± 0.6 p < 0.01	Pre: 7.0 ± 2.3 Post: 15.8 ± 4.1 p < 0.01	Pre: 96.0 ± 43.1 Post: 12.2 ± 6.3 p < 0.01	Grade I: 3 Grade II: 4 Grade III: 1

Note: *Only percentages presented; **not reported as Clavien-Dindo complications.

Abbreviations: ThuFLEP, Thulium Fiber Enucleation of Prostate; HoLEP, Holmium Laser Enucleation of Prostate; OP, Open Prostatectomy; MEP, Monopolar Electroenucleation of Prostate; C-D, Clavien-Dindo; LUTS, Lower Urinary Tract Symptoms; NR, not reported; MOT, mean operative time; PSA, Prostate Specific Antigen; Pre, Preoperative; Post, Postoperative; IPSS, International Prostate Symptom Score; QoL, quality of life; PVR, Post Void Residual.

Discussion

Stone Surgery

Enikeev et al. investigated the clinical efficacy and safety of TFL as a lithotripter during percutaneous nephrolithotomy (PCNL).²⁴ The authors observed no correlation between stone density and LOT or operative time, suggesting that density does not affect the ablation efficiency of TFL. With reference to the theoretical advantages of minimal retropulsion and enhanced visibility of TFL: retropulsion that interfered with operative progress was reported in 1.4% of cases and insignificant retropulsion was reported in 11.7% of cases; and suboptimal visibility was reported in 14.6% of cases, with no significant correlation between frequency and visibility noted. Addressing the safety of TFL, the authors suggested that the high-powered lasers (25–40 W) used for lithotripsy should have no detrimental effect on urinary tissue, with the authors finding no cases of strictures or stenosis at 3 month follow-up.

Shah et al. investigated the use of TFL in mini-percutaneous nephrolithotomy (PCNL) with suction in a prospective study.²¹ The authors sorted through stone sizes using sieves to calibrate the TFL settings to perform mainly dusting and therefore allowing the use of concurrent dust aspiration to decrease operative time. They achieved a 100% stone-free rate at one month, with a mean operative time of 39.9 minutes. Their optimal settings varied with stone density (in Hounsfield Units) ranging from frequencies of 125–200 Hz and a consistent energy of 0.2 J.

Regarding Flexible Ureterorenoscopy with Lithotripsy (FURSL), Enikeev et al. prospectively studied the use of SuperPulsed TFL for 10–30 mm renal calculi, focussing on comparing two regimens for dusting: 0.5 J x 30 Hz = 15 W and 0.15 J x 200 Hz = 30 W.²⁵ They found that both ablation efficiency and speed were higher in 200 Hz mode without the drawbacks of increased laser-on time nor increased intraoperative complication rates. Visibility was comparable between groups, with only 2.5% of cases in the 30 Hz group and 5% of cases in the 200 Hz group having an impairment in visibility.

In a further study, Enikeev et al. analysed the efficacy and safety of SuperPulsed TFL lithotripsy, using a wide variety of pulse frequencies and powers.²⁶ The study found retropulsion to have positive correlation with pulse energy and that decreased visibility was associated only with high retropulsion. There were no reliably predictive indicators of poor visibility identified. The authors concluded that the optimal settings for stone fragmentation were: 0.5 J x 30 Hz and for dusting were: 0.15 J x 100 Hz. Their overall stone-free rate at 3 months was 90%.

Prostate Laser Enucleation

An additional application of TFL is in prostatic enucleation, as demonstrated in Thulium Fiber Laser Enucleation of Prostate (ThuFLEP). As with lithotripsy, Ho:YAG has been the mainstay for endoscopic laser enucleation of prostate (HoLEP) with recurrence rates of less than 5%.²⁷ However, HoLEP is considered technically challenging with a steep learning curve.²⁸ In a randomized study, ThuFLEP was compared with HoLEP and MEP.²² The authors found that ThuFLEP was associated with simple learning curve, achieving proficiency in as few as 8–16 procedures. This illustrates a key advantage over HoLEP which typically requires 50–60 procedures.²⁷ However, the authors found no significant difference in enucleation rates between ThuFLEP and HoLEP. A popular setting for prostate enucleation is 0.5–1J x 30–80Hz.

Enikeev et al retrospectively compared ThuFLEP with Open simple Prostatectomy (OP) for large volume prostate, focussing on comparing lower urinary tract symptoms, quality of life, maximum urine flow rate, and postvoid residual urine volumes.²⁹ The two procedures had comparable operative times and resection speed. ThuFLEP was associated with a shorter hospital stay and catheterisation time when compared to OP. Furthermore, ThuFLEP demonstrated significant improvements in LUTS as measured by International Prostate Symptom Score (IPSS), quality of life, and maximum urine flow rate.

A further study compared ThuFLEP with Transurethral Resection of Prostate (TURP) for BPH, with both modalities being equally effective at resolving LUTS at 6 months postoperatively.²³ Interestingly, patients receiving ThuFLEP had a significant improvement in erectile function on average postoperatively. The authors suggest that this is due to TFL’s shallower penetration depth, allowing safer incisions with a lower risk of surgical capsule penetration and therefore less damaging on neurovascular bundles at the posterolateral surface of the prostate.

Other Applications

Upper Tract Urothelial Carcinoma (UTUC)

Due to the biologically aggressive nature of Upper-Tract Urinary Carcinomas (UTUC),³⁰ radical nephroureterectomy with excision of the bladder cuff (RNU) has been considered the “gold standard” management. The use of risk-stratification approaches to accurately identify patients with low-risk UTUC has allowed the development of kidney-sparing, endoscopic approaches.^31,32 In a retrospective series of 129 patients over 20 years comparing endoscopic versus laparoscopic management of UTUC, the endoscopic group showed high renal preservation (82.5%) at the cost of high local recurrence in five years (49.3% versus 100%) for all tumour grades.³³ However, when broken down by grade, five-year progression-free survival of 100%, 89.4% and 88.9% for the laparoscopic group compared with 96.0%, 58.6% and 55.6% for the endoscopic group highlights the importance of restricting the endoscopic approach for low-grade tumours. In a retrospective study of Ho:YAG laser-based endoscopic photoablation of UTUC, Villa et al. found a progression-free survival rate of 75% vs 52% in patients with low vs high grade tumours, with tumour size >1 cm and multifocality not increasing the risk of disease progression.³⁴ Using Thulium laser as opposed to TFL, for low grade UTUC, Musi et al. found an estimated medial recurrence-free survival of 44 months, with 9.5% progressing to nephroureterectomy.³⁵ In a further study, Wen et al. compared endoscopic management with nephroureterectomy, finding thulium laser treatment to be associated with a lower loss of renal function and a shorter length of stay, but a higher rate of tumour recurrence.³⁶ Despite the promising results for other soft-tissue tumours, endoscopic use of TFL remains unreported for UTUC, although it is likely to be used in the future.

Bladder Tumours

A transurethral approach can be used to manage non-muscle invasive bladder cancer (NMIBC). Conventional transurethral resection of bladder tumour (cTURBT) utilises a piecemeal incisional approach, which confers risks of thermal damage to nearby tissue as well as fragmentation and seeding of the tumour. The risks of local and bloodstream recurrence were quantified by a recent meta-analysis, highlighting a residual tumour prevalence of 48–63%.³⁷ En-bloc resection of the bladder tumour (ERBT) has seen increased uptake since the late 1990s,³⁸ enabled by developments in laser technology. ERBT aims to resect the entire tumour with a 1 cm margin, thus better complying with oncological principles. A recent randomised controlled trial compared cTURBT (using monopolar electrocautery) with Holmium laser ERBT (HolERBT), demonstrating promising results for the laser-based approach.³⁹ HolERBT conferred a lower residual tumour rate (7% vs 27.7%), improved detrusor muscle sampling (98% vs 62%), as well as shorter catheterisation time and hospital stay.

TFL offers several theoretical advantages over Holmium, such as the aforementioned decreased penetration depth and the decreased carbonisation (as a result of better water absorption). Presently, the only results of TFL ERBT are in conference presentations, which demonstrated that TFL was feasible⁷ with no post-operative complications exceeding Clavien-Dindo grade I and a relapse rate of 11.6% at 12 months. At the time of writing, there is a published paper by Enikeev and colleagues who look at the safety and short-term oncological outcomes of TFL for EBRT.⁴⁰

Role of TFL and Areas of Future Research

There are multiple reasons for TFL having a high efficiency for lithotripsy, including higher water-containing tissue ablation, more effective pulse delivery, and less stone retropulsion.⁴¹ The higher water-containing tissue ablation lends itself to vaporising water trapped between stone micro-crystals, within stone cracks, and within crevices on the surface of calculi. When these are vaporised, the mechanical force generated by rapidly increasing pressure leads to further stone ablation.^11,13,15,42 This is an effect which may not be demonstrated by Ho:YAG lasers.⁴³ The second contributing factor is found in the pulse settings possible with TFL. A consistent and constant peak power level over time is found with TFL in contrast to the power spikes generated by Ho:YAG.^15,44 Lastly, the lower stone retropulsion is a contributing factor towards higher lithotripsy efficiency along with the formation of “fine dust” with its use.

While the early TFL results in endourological applications are encouraging, more studies are needed to compare its clinical and safety-related outcomes. Though TFL for stone and BPH use the same system, they have different pulse shape and peak power. Further work on this area is likely to refine and improve the applicability of this technique. As laser machine and fibers can add to the overall cost, this will also need to be taken into account. Apart from comparing the cost of other treatments, patient-related quality of life also needs to be looked at.^45–48 Similarly, comparative studies need to look at the outcomes of TFL with other minimally invasive surgical techniques (MIST) such as prostate artery embolization (PAE) and HOLEP for treatment of BPH.^49,50 In future, there is also a need for more randomised trials and high-quality research using TFL to garner more evidence on its use and applicability.

Conclusion

There is limited evidence on the use and clinical outcomes of TFL. It shows promising results for lithotripsy and prostate treatment, with studies focussed on determining the most appropriate settings and providing initial safety data. Further prospective, randomized research will be needed to assess superiority or non-inferiority to current lithotripsy laser technology and on other applications of TFL, such as in UTUC and en-bloc resection of bladder tumours.

Disclosure

The authors report no conflicts of interest in this work.